Regencell Bioscience HoldingsRGC +31.21%34 Net Current Asset Value is $0.00 as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 613 Drug Manufacturers companies, Regencell Bioscience Holdings ranks worse than 99.51% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Regencell Bioscience Holdings's net current asset value per share for the quarter that ended in Dec. 2025 was $0.00.
The historical rank and industry rank for Regencell Bioscience Holdings's Net Current Asset Value or its related term are showing as below:
RGC'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.42 Med: 22.71 Max: 1704
Current: 799
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Regencell Bioscience Holdings was 1704.00. The lowest was 4.42. And the median was 22.71.
RGC's Price-to-Net-Current-Asset-Value is ranked worse than 99.51% of 613
companies
in the Drug Manufacturers industry
Industry Median: 5.63
vs RGC: 799.00
Regencell Bioscience Holdings (NAS:RGC) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Regencell Bioscience Holdings Net Current Asset Value Related Terms
Regencell Bioscience Holdings Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regencell Bioscience Holdings Net Current Asset Value Chart
RGC vs SUPN, BCRX, PBH: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.00 mean?
Regencell Bioscience Holdings (RGC) has a Net Current Asset Value of $0.00 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Regencell Bioscience Holdings and its competitors. Over the past decade, Regencell Bioscience Holdings' Net Current Asset Value has ranged from 4.42 to 1,704.00. According to the industry distribution chart, Regencell Bioscience Holdings ranks #610 out of 613 companies in the Drug Manufacturers industry, placing it in the top 99.5%.
Is Regencell Bioscience Holdings' Net Current Asset Value too high?
Regencell Bioscience Holdings' current Net Current Asset Value is $0.00. Over the past 10 years, this metric has ranged from a low of 4.42 to a high of 1,704.00. Based on the distribution chart, Regencell Bioscience Holdings ranks #610 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Net Current Asset Value compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #610 out of 613 companies for Net Current Asset Value. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median Net Current Asset Value is 5.63. Historically, Regencell Bioscience Holdings' own Net Current Asset Value has ranged from 4.42 to 1,704.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.63, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current Net Current Asset Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Net Current Asset Value of $0.00. The current Net Current Asset Value is $0.00. Regencell Bioscience Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Net Current Asset Value is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Business Description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
34GF Score
Get the complete analysis for RGC
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
